Diclofenac: an update on its mechanism of action and safety profile

References

• Bergius M, Kiliaridis S, Berggren U. Pain in orthodontics. A review and discussion of the literature. J Orofac Orthop 2000;61:125-37
   PubMedGoogle Scholar
• Dionne RA, Bartoshuk L, Mogil J, et al. Individual responder analyses for pain: does one pain scale fit all?. Trends Pharmacol Sci 2005;26:125-30
   PubMed Web of Science ®Google Scholar
• Agency for Health Care Policy and Research. Acute pain management: operative or medical procedures and trauma, Part 2. Clin Pharmacy 1992;11:391-414
   PubMedGoogle Scholar
• Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
   PubMed Web of Science ®Google Scholar
• IMS Health Inc. IMS National Prescription Audit, 2007 12 months preceding July, 2008
   Google Scholar
• Gottlieb NL. The art and science of nonsteroidal anti-inflammatory drug selection. Semin Arthritis Rheum 1985;15:1-3
   PubMed Web of Science ®Google Scholar
• Barden J, Edwards J, Moore RA, et al. Single dose oral diclofenac for postoperative pain. Cochrane Rev (Online) 2004(2):CD004768
   Google Scholar
• Hinz B, Chevts J, Renner B, et al. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol 2005;59:80-4
   PubMed Web of Science ®Google Scholar
• Macia MA, Frias J, Carcas AJ, et al. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther 1995;33:333-9
   PubMed Web of Science ®Google Scholar
• Mojaverian P, Rocci ML Jr, Conner DP, et al. Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. Clin Pharmacol Ther 1987;41:11-17
   PubMed Web of Science ®Google Scholar
• Sanchez J, Martinez L, Garcia-Barbal J, et al. The influence of gastric emptying on droxicam pharmacokinetics. J Clin Pharmacol 1989;29:739-45
   PubMed Web of Science ®Google Scholar
• Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984;9:404-34
   PubMed Web of Science ®Google Scholar
• Vidon N, Pfeiffer A, Godbillon J, et al. Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application to diclofenac. Br J Clin Pharmacol 1989;28:121-4
   PubMed Web of Science ®Google Scholar
• Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Invest 2007;27:163-95
   PubMed Web of Science ®Google Scholar
• Zipsor™ [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc., July 2009
   Google Scholar
• Kowalski M, Stoker DG, Bon C, et al. A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy [published online ahead of print June 13, 2009]. Am J Ther 2009. doi: 10.1097/MJT.0b013e3181aa3eda
   Google Scholar
• Riff DS, Duckor S, Gottlieb I, et al. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Clin Ther 2009;31:2072-85
   PubMed Web of Science ®Google Scholar
• Voltaren® Gel [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2009
   Google Scholar
• Solaraze® Gel [package insert]. Melville, NY: PharmaDerm, March 2009
   Google Scholar
• Flector® Patch [package insert]. Bristol, TN: King Pharmaceuticals, Inc., July 2009
   Google Scholar
• Pennsaid® Topical Solution. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., November 2009
   Google Scholar
• Jordan S, White J. Non-steroidal anti-inflammatory drugs: clinical issues. Nurs Stand 2001;15:45-52
   Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-5
   Web of Science ®Google Scholar
• Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheum 1996;102:9-21
   Google Scholar
• Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20
   PubMed Web of Science ®Google Scholar
• Tegeder I, Lotsch J, Krebs S, et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther 1999;65:533-44
   PubMed Web of Science ®Google Scholar
• Wittenberg RH, Willburger RE, Kleemeyer KS, et al. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 1993;36:1444-50
   PubMed Web of Science ®Google Scholar
• Ku EC, Lee W, Kothari HV, et al. The effects of diclofenac sodium on arachidonic acid metabolism. Semin Arthritis Rheum 1985;15:36-41
   PubMed Web of Science ®Google Scholar
• Ku EC, Lee W, Kothari HV, et al. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986;80:18-23
   PubMed Web of Science ®Google Scholar
• Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy 2005;25:18-25
   PubMed Web of Science ®Google Scholar
• Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8
   PubMed Web of Science ®Google Scholar
• Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-14
   PubMed Web of Science ®Google Scholar
• Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994;269:13057-60
   PubMed Web of Science ®Google Scholar
• Walsh CE, Dechatelet LR, Thomas MJ, et al. Effect of phagocytosis and ionophores on release and metabolism of arachidonic acid from human neutrophils. Lipids 1981;16:120-4
   PubMed Web of Science ®Google Scholar
• Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta 1987;921:502-11
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Lewis GP. Inhibitory effects of diclofenac and indomethacin on interleukin-1-induced changes in PGE2 release. A novel effect on free arachidonic acid levels in human synovial cells. Biochem Pharmacol 1989;38:3707-11
   PubMed Web of Science ®Google Scholar
• Orido T, Fujino H, Hasegawa Y, et al. Indomethacin decreases arachidonic acid uptake in HCA-7 human colon cancer cells. J Pharmacol Sci 2008;108:389-92
   PubMed Web of Science ®Google Scholar
• Nevalainen TJ, Gronroos JM, Kortesuo PT. Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis. Gut 1993;34:1133-6
   PubMed Web of Science ®Google Scholar
• Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997;57:401-7
   PubMed Web of Science ®Google Scholar
• Kiviniemi H, Ramo OJ, Stahlberg M, et al. Indomethacin in canine acute hemorrhagic pancreatitis. Res Exp Med 1988;188:35-40
   PubMedGoogle Scholar
• Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 2006;1761:1246-59
   PubMed Web of Science ®Google Scholar
• Singh N, Jabeen T, Sharma S, et al. Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7 Å resolution. Acta Crystallogr D 2006;62:410-16
   PubMed Web of Science ®Google Scholar
• Rowlinson SW, Kiefer JR, Prusakiewicz JJ, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003;278:45763-9
   PubMed Web of Science ®Google Scholar
• Triggiani M, Granata F, Frattini A, et al. Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta 2006;1761:1289-300
   PubMed Web of Science ®Google Scholar
• Graham DY, Smith JL, Holmes GI, et al. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharm Ther 1985;38:65-70
   PubMed Web of Science ®Google Scholar
• Hudson N, Balsitis M, Everitt S, et al. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-7
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Fukuda T, Higuchi K, et al. Role of leukotrienes in indomethacin-induced mucosal damage in rats. J Clin Gastroenterol 1993;17:S11-14
   PubMed Web of Science ®Google Scholar
• Rainsford KD. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice. Agents Actions 1987;21:316-19
   PubMedGoogle Scholar
• Pihan G, Rogers C, Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig Dis Sci 1988;33:625-32
   PubMed Web of Science ®Google Scholar
• Liauw HL, Ku E, Brandt KD, et al. Effects of Voltaren on arachidonic acid metabolism in arthritis patients. Agents Actions 1985;17:195-9
   PubMedGoogle Scholar
• Gonzalez E, de la Cruz C, de Nicolas R, et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994;41:171-8
   PubMedGoogle Scholar
• Clish CB, Sun YP, Serhan CN. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. Biochem Biophys Res Commun 2001;288:868-74
   PubMed Web of Science ®Google Scholar
• Salter M, Strijbos PJ, Neale S, et al. The nitric oxide-cyclic GMP pathway is required for nociceptive signalling at specific loci within the somatosensory pathway. Neuroscience 1996;73:649-55
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Nakamura M. I -- Prostaglandin hyperalgesia, a cAMP/Ca2+ dependent process. Prostaglandins 1979;18:179-90
   PubMedGoogle Scholar
• Duarte IDG, Lorenzetti BB, Ferreira SH. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur J Pharmacol 1990;186:289-93
   PubMed Web of Science ®Google Scholar
• Duarte ID, dos Santos IR, Lorenzetti BB, et al. Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 1992;217:225-7
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Duarte ID, Lorenzetti BB. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 1991;201:121-2
   PubMed Web of Science ®Google Scholar
• Tonussi CR, Ferreira SH. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol 1994;251:173-9
   PubMed Web of Science ®Google Scholar
• Asomoza-Espinosa R, Alonso-Lopez R, Mixcoatl-Zecuatl T, et al. Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol 2001;418:195-200
   PubMed Web of Science ®Google Scholar
• Fagni L, Bockaert J. Effects of nitric oxide on glutamate-gated channels and other ionic channels. J Chem Neuroanatomy 1996;10:231-40
   PubMed Web of Science ®Google Scholar
• Armstead WM. Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Am J Physiol 1996;270:H423-6
   PubMedGoogle Scholar
• Carrier GO, Fuchs LC, Winecoff AP, et al. Nitrovasodilators relax mesenteric microvessels by cGMP-induced stimulation of Ca-activated K channels. Am J Physiol 1997;273:H76-84
   PubMedGoogle Scholar
• Soares AC, Duarte ID. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol 2001;134:127-31
   PubMed Web of Science ®Google Scholar
• Granados-Soto V, Flores-Murrieta FJ, Castaneda-Hernandez G, et al. Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac. Eur J Pharmacol 1995;277:281-4
   PubMed Web of Science ®Google Scholar
• Lázaro-Ibáñez GG, Torres-López JE, Granados-Soto V. Participation of the nitric oxide-cyclic GMP-ATP-sensitive K(+) channel pathway in the antinociceptive action of ketorolac. Eur J Pharmacol 2001;426:39-44
   PubMed Web of Science ®Google Scholar
• Ortiz MI, Granados-Soto V, Castaneda-Hernandez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003;76:187-95
   PubMed Web of Science ®Google Scholar
• Deciga-Campos M, Lopez-Munoz FJ. Participation of the L-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib. Eur J Pharmacol 2004;484:193-9
   PubMed Web of Science ®Google Scholar
• Alves DP, Tatsuo MA, Leite R, et al. Diclofenac-induced peripheral antinociception is associated with ATP-sensitive K+ channels activation. Life Sci 2004;74:2577-91
   PubMed Web of Science ®Google Scholar
• Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 2005;107:139-54
   PubMed Web of Science ®Google Scholar
• Okuyama S, Aihara H. The mode of action of analgesic drugs in adjuvant arthritic rats as an experimental model of chronic inflammatory pain: possible central analgesic action of acidic nonsteroidal antiinflammatory drugs. Jpn J Pharmacol 1984;35:95-103
   PubMedGoogle Scholar
• Sacerdote P, Monza G, Mantegazza P, et al. Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations. Pharmacol Res Commun 1985;17:679-84
   PubMedGoogle Scholar
• Martini A, Bondiolotti GP, Sacerdote P, et al. Diclofenac increases beta-endorphin plasma concentrations. J Int Med Res 1984;12:92-5
   PubMed Web of Science ®Google Scholar
• Bjorkman RL, Hedner T, Hallman KM, et al. Localization of the central antinociceptive effects of diclofenac in the rat. Brain Res 1992;590:66-73
   PubMed Web of Science ®Google Scholar
• Yaksh T. Central and peripheral mechanisms for the antialgesic action of acetylsalicylic acid. In: Barnett H, Hirsch J, Mustard J, eds. Acetylsalicylic Acid: New Uses for an Old Drug. New York: Raven, 1982:137-51
   Google Scholar
• Vescovi P, Passeri M, Gerra G, et al. Naloxone inhibits the early phase of diclofenac analgesia in man. Pain Clin 1986;87:151-5
   Google Scholar
• Dionne RA, McCullagh L. Enhanced analgesia and suppression of plasma beta-endorphin by the S(+)-isomer of ibuprofen. Clin Pharmacol Ther 1998;63:694-701
   PubMed Web of Science ®Google Scholar
• Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand 1995;103:1-44
   Google Scholar
• Bjorkman R, Hallman KM, Hedner J, et al. Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat. J Clin Pharmacol 1996;36:20S-26S
   PubMed Web of Science ®Google Scholar
• Dong X-D. The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism. Pain 2009;147:36-45
   PubMed Web of Science ®Google Scholar
• Edwards SR, Mather LE, Lin Y, et al. Glutamate and kynurenate in the rat central nervous system following treatments with tail ischaemia or diclofenac. J Pharm Pharmacol 2000;52:59-66
   PubMed Web of Science ®Google Scholar
• Nasstrom J, Karlsson U, Post C. Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice. Eur J Pharmacol 1992;212:21-9
   PubMed Web of Science ®Google Scholar
• Schwieler L, Erhardt S, Erhardt C, et al. Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 2005;112:863-72
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11
   PubMed Web of Science ®Google Scholar
• Ledwith BJ, Pauley CJ, Wagner LK, et al. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem 1997;272:3707-14
   PubMed Web of Science ®Google Scholar
• Callejas NA, Castrillo A, Bosca L, et al. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators. J Pharmacol Exp Ther 1999;288:1235-41
   PubMed Web of Science ®Google Scholar
• Pontsler AV, St Hilaire A, Marathe GK, et al. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 2002;277:13029-36
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-6
   PubMed Web of Science ®Google Scholar
• Wick M, Hurteau G, Dessev C, et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002;62:1207-14
   PubMed Web of Science ®Google Scholar
• Adamson DJ, Frew D, Tatoud R, et al. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 2002;61:7-12
   PubMed Web of Science ®Google Scholar
• Kojo H, Fukagawa M, Tajima K, et al. Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). J Pharmacol Sci 2003;93:347-55
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Kusunoki N, Matsuzaki T, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther 2002;302:18-25
   PubMed Web of Science ®Google Scholar
• Na HK, Surh YJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 2003;66:1381-91
   PubMed Web of Science ®Google Scholar
• Ayoub SS, Botting RM, Joshi AN, et al. Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines. Mol Cell Biochem 2009;327:101-10
   PubMed Web of Science ®Google Scholar
• O’Connor TM, O’Connell J, O’Brien DI, et al. The role of substance P in inflammatory disease. J Cell Phys 2004;201:167-80
   PubMed Web of Science ®Google Scholar
• Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001;33:555-76
   PubMed Web of Science ®Google Scholar
• Marshall KW, Chiu B, Inman RD. Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum 1990;33:87-90
   PubMed Web of Science ®Google Scholar
• Sacerdote P, Carrabba M, Galante A, et al. Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac and naproxen. Inflamm Res 1995;44:486-90
   PubMed Web of Science ®Google Scholar
• Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991;43:143-201
   PubMed Web of Science ®Google Scholar
• Locatelli L, Sacerdote P, Mantegazza P, et al. Effect of ibuprofen and diclofenac on the chemotaxis induced by substance P and transforming growth factor-beta on human monocytes and polymorphonuclear cells. Int J Immunopharmacol 1993;15:833-8
   PubMed Web of Science ®Google Scholar
• Locatelli L, Sacerdote P, Panerai AE. Effects of indomethacin and diclofenac on substance P induced chemotaxis of human monocytes and polymorphonuclear cells. Pharmacol Res 1992;25:97-8
   PubMed Web of Science ®Google Scholar
• Andoh T, Katsube N, Maruyama M, et al. Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117:1621-6
   PubMed Web of Science ®Google Scholar
• Papworth J, Colville-Nash P, Alam C, et al. The depletion of substance P by diclofenac in the mouse. Eur J Pharmacol 1997;325:R1-R2
   PubMed Web of Science ®Google Scholar
• Komatsu H, Yaju H, Chiba K, et al. Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells. Int J Immunopharmacol 1991;13:1137-46
   PubMed Web of Science ®Google Scholar
• Tsuboi I, Tanaka H, Nakao M, et al. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine 1995;7:372-9
   PubMed Web of Science ®Google Scholar
• Henrotin Y, de Leval X, Mathy-Hartet M, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 2001;50:391-9
   PubMed Web of Science ®Google Scholar
• Mahdy AM, Galley HF, Abdel-Wahed MA, et al. Differential modulation of interleukin-6 and interleukin-10 by diclofenac in patients undergoing major surgery. Br J Anaesth 2002;88:797-802
   PubMed Web of Science ®Google Scholar
• Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996;72:171-91
   PubMed Web of Science ®Google Scholar
• Selg E, Buccellati C, Andersson M, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol 2007;152:1185-95
   PubMed Web of Science ®Google Scholar
• Voilley N, de Weille J, Mamet J, et al. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 2001;21:8026-33
   PubMed Web of Science ®Google Scholar
• Dorofeeva NA, Barygin OI, Staruschenko A, et al. Mechanisms of non-steroid anti-inflammatory drugs action on ASICs expressed in hippocampal interneurons. J Neurochem 2008;106:429-41
   PubMed Web of Science ®Google Scholar
• Jones NG, Slater R, Cadiou H, et al. Acid-induced pain and its modulation in humans. J Neurosci 2004;24:10974-9
   PubMed Web of Science ®Google Scholar
• Steen KH, Reeh PW, Kreysel HW. Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. Pain 1995;62:339-47
   PubMed Web of Science ®Google Scholar
• Verburg KM, Maziasz TJ, Weiner E, et al. Cox-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001;8:49-64
   PubMedGoogle Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-32
   PubMed Web of Science ®Google Scholar
• Ong CK, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007;5:19-34
   PubMedGoogle Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs?. BMJ (Clinical Research Edition) 2002;324:1287-8
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28
   PubMed Web of Science ®Google Scholar
• Laine L, Smith R, Min K, et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006;24:751-67
   PubMed Web of Science ®Google Scholar
• Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?. Postgrad Med 2006;82:186-91
   Google Scholar
• Bjarnason I, Hayllar J, Macpherson AJ. Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6
   PubMed Web of Science ®Google Scholar
• Lanas A, Sopena F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin of North Am 2009;38:333-52
   PubMed Web of Science ®Google Scholar
• Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;26:2104-10
   Google Scholar
• Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008;135:1517-25
   PubMed Web of Science ®Google Scholar
• Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9
   PubMed Web of Science ®Google Scholar
• Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-12
   PubMed Web of Science ®Google Scholar
• Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med 2004;117:72S-78S
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-77
   PubMed Web of Science ®Google Scholar
• Ueno N, Murakami M, Tanioka T, et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 2001;276:34918-27
   PubMed Web of Science ®Google Scholar
• Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41
   PubMed Web of Science ®Google Scholar
• van der Hoorn JW, Jukema JW, Bekkers ME, et al. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Crit Care Med 2008;36:2576-82
   PubMed Web of Science ®Google Scholar
• Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009;48:425-32
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85:190-7
   PubMed Web of Science ®Google Scholar
• Rao RM, Yang L, Garcia-Cardena G, et al. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007;101:234-47
   PubMed Web of Science ®Google Scholar
• Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988;35:244-85
   PubMed Web of Science ®Google Scholar
• Friman C, Johnston C, Chew C, et al. Effect of diclofenac sodium, tolfenamic acid and indomethacin on the production of superoxide induced by N-formyl-methionyl-leucyl-phenylalanine in normal human polymorphonuclear leukocytes. Scand J Rheumatol 1986;15:41-6
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez F, Gonzalez-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995;95:1756-65
   PubMed Web of Science ®Google Scholar
• Sakai A. Diclofenac inhibits endothelial cell adhesion molecule expression induced with lipopolysaccharide. Life Sci 1996;58:2377-87
   PubMed Web of Science ®Google Scholar
• Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-5
   PubMed Web of Science ®Google Scholar
• Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998;20:376-87
   PubMed Web of Science ®Google Scholar
• Martinez LL, Oliveira MA, Miguel AS, et al. Enalapril interferes with the effect of diclofenac on leucocyte-endothelium interaction in hypertensive rats. J Cardiovasc Pharmacol 2004;43:258-65
   PubMed Web of Science ®Google Scholar
• Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S
   PubMedGoogle Scholar
• Rossat J, Maillard M, Bussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84
   PubMed Web of Science ®Google Scholar
• Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly person receiving a low-salt diet. Ann Intern Med 2000;133:1-9
   PubMed Web of Science ®Google Scholar
• Dilger K, Herrliinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 2002;42:985-94
   PubMed Web of Science ®Google Scholar
• Lee A, Cooper MG, Craig JC, et al. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Rev (Online) 2007:1-41
   Google Scholar
• Whelton A, Lefkowith JL, West CR, et al. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006;70:1495-502
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicicity. N Engl J Med 1995;333:1118-27
   PubMed Web of Science ®Google Scholar
• Zimmerman HJ. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 1990;10:322-38
   PubMed Web of Science ®Google Scholar
• Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005;3:489-98
   PubMed Web of Science ®Google Scholar
• Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy, and safety. Clin Drug Invest 2007;27:163-95
   PubMed Web of Science ®Google Scholar
• Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury?. Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009;104:356-62
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki MB, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• Zacher J, Altman R, Bellamy N, et al. Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin 2008;24:925-50
   PubMed Web of Science ®Google Scholar
• Moen MD. Topical diclofenac solution. Drugs 2009;69:2621-32
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation diclofenac epolamine. Curr Med Res Opin 2008;24:2967-92
   PubMed Web of Science ®Google Scholar
• Tugwell PS, Wells GA, Shainshouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002-12
   PubMed Web of Science ®Google Scholar
• Kienzler J-L, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010;50:50-61
   PubMed Web of Science ®Google Scholar
• McCormack K, Brune K. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. Drugs 1991;41:533-47
   PubMed Web of Science ®Google Scholar
• Clarke GD, MacPherson IS, Petrone G, et al. Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation. Eur J Pharmacol 1994;257:103-8
   PubMed Web of Science ®Google Scholar
• Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy?. Trends Pharmacol Sci 1999;20:4-6
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7
   PubMed Web of Science ®Google Scholar